CCR2 and metabolic dysfunction-associated steatohepatitis: Hopefully, the dual CCR2/5 inhibitor cenicriviroc was well tolerated in NASH patients and is currently undergoing a phase III clinical trial (NCT03028740) (Ratziu et al., 2020).